06.27.25 -- How A Biotech Navigates The CDMO Frenzy For GLP-1 Services

Picking and sticking are the most common tablet defects that can reduce your product quality and performance. This makes perfecting the right pre-picking strategy essential to improving your processes.

Examine challenges and key considerations for spray-dried formulations for inhalation, along with a review of current technologies and approved products utilizing particle engineering approaches.

Review a commercially-ready process capable of reproducing spray-dried dispersions with less manufacturing complexity and environmental impact, and out-designing and outperforming spray drying.

Learn where biotechs encounter the most hiccups when it comes to meeting all the compliance processes and regulations with your outsourcing partners.

Creating a greener manufacturing platform that accommodates solvent recovery and recycling requires careful consideration of your resources, procedures, and partnerships to achieve cost-effective goals.

Partner with an experienced CDMO to streamline development, reduce risk, and accelerate your drug’s path to market in today’s complex and competitive pharmaceutical landscape.

Ensuring critical OSD therapeutics reach patients successfully relies on the ability of developers and manufacturers to navigate the inherent issues surrounding their increasing complexity.

With a Ph.D. in bioanalytical chemistry from the University of Alaska Fairbanks, Kirschner brings nearly 15 years of experience in pharmaceutical development across the biotech and CDMO sectors.

Tom Sellig discusses the ongoing relevance of small molecules, oral solid dose development, trends like GLP-1, and innovations like 3D printing in pharmaceuticals.

Explore how advanced high-potency capabilities and specialized expertise are driving the development and manufacturing of next-generation ADC payloads and linkers.